Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours

BackgroundAlthough metabolism is profoundly altered in human liver cancer, the extent to which experimental models, e.g. cell lines, mimic those alterations is unresolved. Here, we aimed to determine the resemblance of hepatocellular carcinoma (HCC) cell lines to human liver tumours, specifically in the expression of deregulated metabolic targets in clinical tissue samples.MethodsWe compared the overall gene expression profile of poorly-differentiated (HLE, HLF, SNU-449) to well-differentiated (HUH7, HEPG2, HEP3B) HCC cell lines in three publicly available microarray datasets. Three thousand and eighty-five differentially expressed genes in ≥2 datasets (P < 0.05) were used for pathway enrichment and gene ontology (GO) analyses. Further, we compared the topmost gene expression, pathways, and GO from poorly differentiated cell lines to the pattern from four human HCC datasets (623 tumour tissues). In well- versus poorly differentiated cell lines, and in representative models HLE and HUH7 cells, we specifically assessed the expression pattern of 634 consistently deregulated metabolic genes in human HCC. These data were complemented by quantitative PCR, proteomics, metabolomics and assessment of response to thirteen metabolism-targeting compounds in HLE versus HUH7 cells.ResultsWe found that poorly-differentiated HCC cells display upregulated MAPK/RAS/NFkB signaling, focal adhesion, and downregulated complement/coagulation cascade, PPAR-signaling, among pathway alterations seen in clinical tumour datasets. In HLE cells, 148 downregulated metabolic genes in liver tumours also showed low gene/protein expression – notably in fatty acid β-oxidation (e.g. ACAA1/2, ACADSB, HADH), urea cycle (e.g. CPS1, ARG1, ASL), molecule transport (e.g. SLC2A2, SLC7A1, SLC25A15/20), and amino acid metabolism (e.g. PHGDH, PSAT1, GOT1, GLUD1). In contrast, HUH7 cells showed a higher expression of 98 metabolic targets upregulated in tumours (e.g. HK2, PKM, PSPH, GLUL, ASNS, and fatty acid synthesis enzymes ACLY, FASN). Metabolomics revealed that the genomic portrait of HLE cells co-exist with profound reliance on glutamine to fuel tricarboxylic acid cycle, whereas HUH7 cells use both glucose and glutamine. Targeting glutamine pathway selectively suppressed the proliferation of HLE cells.ConclusionsWe report a yet unappreciated distinct expression pattern of clinically-relevant metabolic genes in HCC cell lines, which could enable the identification and therapeutic targeting of metabolic vulnerabilities at various liver cancer stages.

[1]  O. Sagol,et al.  Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion , 2009, BMC Cancer.

[2]  N. Iizuka,et al.  Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. , 2008, International journal of oncology.

[3]  S. Thorgeirsson,et al.  Transforming growth factor‐β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer , 2008, Hepatology.

[4]  M. Ozturk,et al.  Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells , 2009, Molecular Cancer.

[5]  B. Viollet,et al.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. , 2010, The Journal of clinical investigation.

[6]  M. Weller,et al.  Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer , 2010, International journal of cancer.

[7]  Gregory Stephanopoulos,et al.  Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis , 2012, BMC Proceedings.

[8]  Abhishek K. Jha,et al.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011, Nature.

[9]  T. Fan,et al.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. , 2012, Cell metabolism.

[10]  C. Meyer,et al.  Distinct dedifferentiation processes affect caveolin-1 expression in hepatocytes , 2013, Cell Communication and Signaling.

[11]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[12]  W. Marston Linehan,et al.  Reductive carboxylation supports growth in tumor cells with defective mitochondria , 2011, Nature.

[13]  Takashi Tsukamoto,et al.  Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. , 2012, Cell metabolism.

[14]  Xin Lu,et al.  Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. , 2013, Cancer research.

[15]  Matthew G. Vander Heiden,et al.  Metabolic targets for cancer therapy , 2013, Nature Reviews Drug Discovery.

[16]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[17]  B. Jiang,et al.  Insulin Promotes Glucose Consumption via Regulation of miR-99a/mTOR/PKM2 Pathway , 2013, PloS one.

[18]  J. Dering,et al.  Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro , 2013, Hepatology.

[19]  S. Dooley,et al.  Comparative Analysis of TGF-β/Smad Signaling Dependent Cytostasis in Human Hepatocellular Carcinoma Cell Lines , 2013, PloS one.

[20]  Eytan Ruppin,et al.  A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration , 2014, Molecular Systems Biology.

[21]  Jennifer B Dennison,et al.  Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer , 2014, Molecular Cancer Therapeutics.

[22]  Eytan Ruppin,et al.  A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration , 2014, Molecular systems biology.

[23]  J. Llovet,et al.  Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design , 2014, Clinical Cancer Research.

[24]  A. Arcangeli,et al.  Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts , 2014, British Journal of Cancer.

[25]  M. V. Heiden,et al.  Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells , 2015, Cell.

[26]  Keigo Saito,et al.  Biomarkers for the early diagnosis of hepatocellular carcinoma. , 2015, World journal of gastroenterology.

[27]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[28]  J. Zucman‐Rossi,et al.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. , 2015, Gastroenterology.

[29]  E Holmes,et al.  Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review , 2015, British Journal of Cancer.

[30]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[31]  D. Sabatini,et al.  An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis , 2015, Cell.

[32]  N. Battello,et al.  The role of HIF-1 in oncostatin M-dependent metabolic reprogramming of hepatic cells , 2016, Cancer & metabolism.

[33]  C. Thompson,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[34]  Bruno Clément,et al.  Integrative Genomic Analysis Identifies the Core Transcriptional Hallmarks of Human Hepatocellular Carcinoma. , 2016, Cancer research.

[35]  Chi V. Dang,et al.  From Krebs to clinic: glutamine metabolism to cancer therapy , 2016, Nature Reviews Cancer.

[36]  B. Sitek,et al.  Quantitative proteome analysis reveals the correlation between endocytosis-associated proteins and hepatocellular carcinoma dedifferentiation. , 2016, Biochimica et biophysica acta.

[37]  S. Dooley,et al.  TGF-β1 and TGF-β2 abundance in liver diseases of mice and men , 2016, Oncotarget.

[38]  N. Hay,et al.  Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? , 2016, Nature Reviews Cancer.

[39]  Antoine de Weck,et al.  Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening , 2017, Cell.

[40]  Matthew G. Vander Heiden,et al.  Understanding the Intersections between Metabolism and Cancer Biology , 2017, Cell.

[41]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[42]  Jun Kikuchi,et al.  NMR-Based Metabolic Profiling of Field-Grown Leaves from Sugar Beet Plants Harbouring Different Levels of Resistance to Cercospora Leaf Spot Disease , 2017, Metabolites.

[43]  D. Morvan,et al.  Specificities of Human Hepatocellular Carcinoma Developed on Non-Alcoholic Fatty Liver Disease in Absence of Cirrhosis Revealed by Tissue Extracts 1H-NMR Spectroscopy , 2017, Metabolites.

[44]  Barbara Sitek,et al.  Identification of the Consistently Altered Metabolic Targets in Human Hepatocellular Carcinoma , 2017, Cellular and molecular gastroenterology and hepatology.

[45]  J. Rabinowitz,et al.  Metabolomics and Isotope Tracing , 2018, Cell.

[46]  Zhongming Zhao,et al.  Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers , 2018, Cell reports.

[47]  J. Gingold,et al.  Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. , 2018, Trends in molecular medicine.

[48]  P. Galle,et al.  The role of molecular enrichment on future therapies in hepatocellular carcinoma. , 2018, Journal of hepatology.